Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9185883 | 0.88 | KMT2A (0.56) | MEN1KMT2APOLBSMN1; SMN2L3MBTL1 | |
| SCHEMBL15303135 | 0.85 | TDP1 (0.51) | MEN1KMT2APOLBSMN1; SMN2L3MBTL1 | |
| SCHEMBL29209739 | 0.84 | RXFP1 (0.47) | MEN1KMT2APOLBSMN1; SMN2L3MBTL1 | |
| SCHEMBL7709283 | 0.83 | MAPT (0.46) | MEN1KMT2APOLBSMN1; SMN2MAPT | |
| SCHEMBL7709281 | 0.83 | MAPT (0.46) | MEN1KMT2APOLBSMN1; SMN2MAPT | |
| SCHEMBL249599 | 0.82 | KCNMA1 (0.56) | MEN1KMT2APOLBSMN1; SMN2L3MBTL1 | |
| SCHEMBL5144247 | 0.82 | KCNMA1 (0.63) | MEN1KMT2APOLBSMN1; SMN2L3MBTL1 | |
| SCHEMBL30388557 | 0.82 | KCNMA1 (0.63) | MEN1KMT2APOLBSMN1; SMN2L3MBTL1 | |
| SCHEMBL9872830 | 0.81 | MEN1 (0.50) | MEN1KMT2APOLBSMN1; SMN2L3MBTL1 | |
| SCHEMBL601548 | 0.81 | KMT2A (0.50) | MEN1KMT2APOLBSMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110305018-B | Preparation method of 3-bromo-2-fluoronitrobenzene | 浙江普洛家园药业有限公司 | 2022-07-15 | — | — | CN | claimed |
| CN-118684581-A | Method for preparing ultra-high purity 3-bromo-2-fluoronitrobenzene by coupling melt crystallization | 天津科技大学 | 2024-09-24 | — | — | CN | disclosed |
| CN-110305018-B | Preparation method of 3-bromo-2-fluoronitrobenzene | 浙江普洛家园药业有限公司 | 2022-07-15 | — | — | CN | disclosed |
| CN-110305018-B | Preparation method of 3-bromo-2-fluoronitrobenzene | 浙江普洛家园药业有限公司 | 2022-07-15 | — | — | CN | disclosed |
| US-20200155525-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC | 2020-05-21 | — | — | US | disclosed |
| US-10654832-B2 | 3-(benzoimidazol-2-YL)-indazole inhibitors of the Wnt signaling pathway and therapeutic uses thereof | SAMUMED, LLC (US) | 2020-05-19 | — | — | US | disclosed |
| US-20190352279-A1 | 3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2019-11-21 | — | — | US | disclosed |
| US-10392383-B2 | 3-(1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-08-27 | — | — | US | disclosed |
| EP-2770994-B1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED LLC (US) | 2019-08-21 | — | — | EP | disclosed |
| US-10342788-B2 | 1H-pyrazolo[3,4-b]pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-07-09 | — | — | US | disclosed |
| US-20060211712-A1 | Bicyclic anilide spirohydantoin cgrp receptor antagonists | MERCK SHARP & DOHME LLC | 2006-09-21 | — | — | US | disclosed |
| US-7094763-B2 | Substituted fused heterocyclic C-glycosides | JANSSEN PHARACEUTICA, N.V. (BE) | 2006-08-22 | — | — | US | disclosed |
| EP-1679965-A2 | SUBSTITUTED FUSED HETEROCYCLIC C-GLYCOSIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-19 | — | — | EP | disclosed |
| EP-1608627-A2 | BICYCLIC ANILIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | Merck & Co. Inc. (US) | 2005-12-28 | — | — | EP | disclosed |
| US-20050037980-A1 | Substituted fused heterocyclic C-glycosides | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-17 | — | — | US | disclosed |
| WO-2005012318-A2 | SUBSTITUTED FUSED HETEROCYCLIC C-GLYCOSIDES | JANSSEN PHARMACEUTICA NV (BE) | 2005-02-10 | — | — | WO | disclosed |
| WO-2004082605-A2 | BICYCLIC ANILIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | MERCK & CO. INC. (US) | 2004-09-30 | — | — | WO | disclosed |
| US-6441017-B1 | Inhibitors of prenyl-protein transferase | MERCK & CO., INC. | 2002-08-27 | — | — | US | disclosed |
| EP-1214326-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 2002-06-19 | — | — | EP | disclosed |
| WO-2001018006-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2001-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352279-A1 | 3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | MEN1 4360/4885KMT2A 4180/4885POLB 2295/4885 |
| US-10392383-B2 | 3-(1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof | WNT1, WNT3, WNT3A | MEN1 4394/4885KMT2A 3108/4885POLB 3221/4885 |
| US-10342788-B2 | 1H-pyrazolo[3,4-b]pyridines and therapeutic uses thereof | COL1A1, NOX4, FGF1 | MEN1 1889/4885KMT2A 4492/4885POLB 2204/4885 |
| US-20060211712-A1 | Bicyclic anilide spirohydantoin cgrp receptor antagonists | BDKRB2, CALCRL, CCKBR | MEN1 1113/4885KMT2A 4223/4885POLB 4642/4885 |
| US-10654832-B2 | 3-(benzoimidazol-2-YL)-indazole inhibitors of the Wnt signaling pathway and therapeutic uses thereof | WNT1, WNT3, WNT3A | MEN1 4360/4885KMT2A 4180/4885POLB 2295/4885 |
| US-20200155525-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | COL1A1, NOX4, FGF1 | MEN1 1889/4885KMT2A 4492/4885POLB 2204/4885 |
| US-20050037980-A1 | Substituted fused heterocyclic C-glycosides | UGCG, UGGT1, GCG | MEN1 2465/4885KMT2A 4431/4885POLB 4559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.